Navigation Links
/C O R R E C T I O N -- Nycomed/
Date:9/10/2009

In the news release, "First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain" issued on 9 Sep 2009 07:00 GMT, by Nycomed over PR Newswire, we are advised by a representative of the company that the first set of bullet points should read "The median number of BTCP episodes per patient per day was 3; Each episode had a median duration of 60 minutes; 96% of the pain episodes were described as moderate to severe; For 90% of patients their BTCP interfered with their daily living including their ability to sleep, walk and get on with other people" and the second set of bullet points should read "At least 95% of patients were using orally administered drugs; "The time to first noticing a reduction in pain had a median time of 20 minutes; In this survey the median time to peak effect of the current BTCP rescue medications was 30 minutes". In addition, the fourth paragraph should read "For this kind of pain episode the ideal treatment would be fast acting with a short duration of action to most closely match the nature of BTCP episodes" instead of "For this kind of pain episode the ideal treatment would be fast acting with short duration of action to most closely match the nature of BTCP episodes" as incorrectly transmitted by PR Newswire. Complete, corrected release follows:

, /PRNewswire/ --

- Choosing a More Appropriate Route of Administration for Fast Acting Pain Relief Could be the key to Improvement

The first results of the first European survey of cancer patients' experience of breakthrough pain[1] were presented today at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090909/358726 )

Previous surveys have looked at the overall management of pain in cancer patients but this is the first international study to look in detail at Breakthrough Cancer Pain (BTCP) from a patient perspective. These results for the first 200 patients from the UK, Sweden and Denmark offer valuable insight into cancer patients' experiences with breakthrough pain management and the impact of the condition on their daily lives.

    - The median number of BTCP episodes per patient per day was 3

    - Each episode had a median duration of 60 minutes

    - 96% of the pain episodes were described as moderate to severe

    - For 90% of patients their BTCP interfered with their daily living
      including their ability to sleep, walk and get on with other people

"The study documents that breakthrough pain has a significant impact on cancer patients' daily lives," explained Dr. Andrew Davies, Department of Palliative Medicine, Royal Marsden Hospital, UK and the principal investigator of this survey. "Breakthrough pain is very different to background pain. Background pain is a continuous, chronic pain requiring around-the-clock medication. Breakthrough pain is a fast onset, short duration, intense pain that breaks through the chronic pain even when this is being controlled with medication. It is incapacitating and very distressing to the patient."

For this kind of pain episode the ideal treatment would be fast acting with a short duration of action to most closely match the nature of BTCP episodes. Moreover, it must be easy to use to improve patient compliance. However, the results of the survey show that:

    - At least 95% of patients were using orally administered drugs
    - The time to first noticing a reduction in pain had a median time of
      20 minutes
    - In this survey the median time to peak effect of the current BTCP
      rescue medications was 30 minutes

"Oral opioids are still commonly used to manage BTCP despite the fact that the way these drugs work does not match the characteristics of a BTCP episode. Opioids given by other routes, for example intranasal, have significant advantages over oral opioids and the interim results from this survey suggest that these routes would be suitable for and welcomed by the majority of cancer patients with breakthrough pain," said Dr. Andrew Davies.

The European Survey of Breakthrough Cancer Pain is continuing to recruit patients in Germany and Ireland and will expand into Austria, Belgium, Czech Republic, Finland, France, Greece, the Netherlands, Norway, Portugal, Spain and Switzerland to provide health care professionals across Europe with patient insights on the management of breakthrough cancer pain.

About Nycomed

Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Its R&D is built to be open for partnerships as in-licensing is a cornerstone in the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed will further strengthen its position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated in 2008 total sales of EUR 3.4 billion and an adjusted EBITDA of EUR 1.2 billion.

For more information please visit http://www.nycomed.com

References

1. Davies A et al. European survey of oncology patient's experience of breakthrough cancer pain: UK, SE and DK results. Poster presented at EFIC 2009.

    About the survey

    - First phase of an ongoing, multicentre observational study

    - First five countries include: UK, Sweden, Denmark, Germany, Ireland

    - 11 palliative care units

    - 400 patients with breakthrough cancer pain

    - Data collected on breakthrough cancer pain and treatment of
      breakthrough cancer pain

    - First results are based on 200 patients from UK (80), Sweden (80) and
      Denmark (40)

    - The study is supported by an educational grant from Nycomed.

For further information:

Media: Ulf Jonson, Senior International Brand Manager, Nycomed: +45-46-77-10-78

------

First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain

LISBON, Portugal, September 9 /PRNewswire/ --

- Choosing a More Appropriate Route of Administration for Fast Acting Pain Relief Could be the key to Improvement

The first results of the first European survey of cancer patients' experience of breakthrough pain[1] were presented today at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090909/358726 )

Previous surveys have looked at the overall management of pain in cancer patients but this is the first international study to look in detail at Breakthrough Cancer Pain (BTCP) from a patient perspective. These results for the first 200 patients from the UK, Sweden and Denmark offer valuable insight into cancer patients' experiences with breakthrough pain management and the impact of the condition on their daily lives.

    - On average each patient had 3 episodes of BTCP per day

    - Each episode had an average duration of 60 minutes

    - 96% of the pain episodes were described as moderate to severe

    - For 87% of patients their BTCP interfered with their daily living
      including their ability to sleep, walk and get on with other people

"The study documents that breakthrough pain has a significant impact on cancer patients' daily lives," explained Dr. Andrew Davies, Department of Palliative Medicine, Royal Marsden Hospital, UK and the principal investigator of this survey. "Breakthrough pain is very different to background pain. Background pain is a continuous, chronic pain requiring around-the-clock medication. Breakthrough pain is a fast onset, short duration, intense pain that breaks through the chronic pain even when this is being controlled with medication. It is incapacitating and very distressing to the patient."

For this kind of pain episode the ideal treatment would be fast acting with short duration of action to most closely match the nature of BTCP episodes. Moreover, it must be easy to use to improve patient compliance. However, the results of the survey show that:

    - 98% of patients were using orally administered drugs
    - The time to first noticing a reduction in pain was on average 20
      minutes
    - The time to knowing that the pain medication was really making a
      difference was on average 30 minutes or half way through the typical
      BTCP episode observed in this survey

"Oral opioids are still commonly used to manage BTCP despite the fact that the way these drugs work does not match the characteristics of a BTCP episode. Opioids given by other routes, for example intranasal, have significant advantages over oral opioids and the interim results from this survey suggest that these routes would be suitable for and welcomed by the majority of cancer patients with breakthrough pain," said Dr. Andrew Davies.

The European Survey of Breakthrough Cancer Pain is continuing to recruit patients in Germany and Ireland and will expand into Austria, Belgium, Czech Republic, Finland, France, Greece, the Netherlands, Norway, Portugal, Spain and Switzerland to provide health care professionals across Europe with patient insights on the management of breakthrough cancer pain.

About Nycomed

Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Its R&D is built to be open for partnerships as in-licensing is a cornerstone in the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed will further strengthen its position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated in 2008 total sales of EUR 3.4 billion and an adjusted EBITDA of EUR 1.2 billion.

For more information please visit http://www.nycomed.com

References

1. Davies A et al. European survey of oncology patient's experience of breakthrough cancer pain: UK, SE and DK results. Poster presented at EFIC 2009.

    About the survey

    - First phase of an ongoing, multicentre observational study

    - First five countries include: UK, Sweden, Denmark, Germany, Ireland

    - 11 palliative care units

    - 400 patients with breakthrough cancer pain

    - Data collected on breakthrough cancer pain and treatment of
      breakthrough cancer pain

    - First results are based on 200 patients from UK (80), Sweden (80) and
      Denmark (40)

    - The study is supported by an educational grant from Nycomed.

For further information:

Media: Ulf Jonson, Senior International Brand Manager, Nycomed: +45-46-77-10-78


'/>"/>
SOURCE Nycomed
Copyright©2009 PR Newswire.
All rights reserved

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Opelousas, LA (PRWEB) , ... February 12, 2016 , ... ... of St. Landry and Evangeline Parishes. The purpose of these scholarships is to ... to encourage those individuals to seek employment within these two parishes. , “We ...
(Date:2/12/2016)... Boca Raton, FL (PRWEB) , ... February 12, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – hosted over 250 members of South Florida’s philanthropic community at ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... the life cycle of pharmaceutical products, garnering increased attention from all stakeholders in ...
(Date:2/12/2016)... ... 2016 , ... As a former television executive, owner Tal Rabinowitz knows how ... to decompress, Rabinowitz found herself drawn to a casual meditation class while working at ... life, implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a technology and ... the ISE Southeast Awards 2016. Finalists and winners of the ISE® Awards for ... Forum and Awards Gala on March 15, 2016 at the Westin Peachtree Plaza, ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- The primary goal of this research is to ... usage of liquid biopsy. Key information the survey seeks ... of liquid biopsy adoption amidst future users - Predominantly ... - Sample inflow to conduct liquid biopsy tests - ... so on. - Correlation analysis of sample type and ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016  Walgreens has ... across 39 states and Washington, D.C. ... a move that was commended by shareholder advocacy organization As ... at As You Sow. "Many people hold on to unneeded ... which can have tragic consequences." --> Conrad ...
(Date:2/11/2016)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... birth tissues, human skin and bone, and patent-protected processes ... and therapies, announced today that it will present at ... New York , NY.  Parker H. ... , Chief Financial Officer and Chris Cashman , ...
Breaking Medicine Technology: